Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction.
Sign Up to like & getrecommendations! Published in 2022 at "Pain"
DOI: 10.1097/j.pain.0000000000002614
Abstract: ABSTRACT Galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, is an emerging migraine preventative. We hypothesized that the preventive effects are conveyed via modulation of somatosensory processing and that certain sensory profiles may hence be… read more here.
Keywords: clinical response; trigeminal sensory; sensory modulatory; modulatory effects ... See more keywords